Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor

Infectious Disease Clinics of North America

Volumn 17, Issue 1, 2003, Pages 87-112

  Vander Straten, Melody R ^a   Hossain, Mohammad A ^a   Ghannoum, Mahmoud A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMMONIUM LACTATE; ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; CICLOPIROX; CISAPRIDE; CLOTRIMAZOLE; CYCLOSPORIN; DIAZEPAM; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KERATIN; KETOCONAZOLE; MEVINOLIN; MICONAZOLE; MIDAZOLAM; NAFTIFINE; ORAL CONTRACEPTIVE AGENT; POTASSIUM HYDROXIDE; RIFABUTIN; SELENIUM SULFIDE; SIMVASTATIN; TACROLIMUS; TERBINAFINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRALGIA; CONFUSION; DERMATOMYCOSIS; DIARRHEA; DRY SKIN; DYSPEPSIA; EPIDERMOPHYTON FLOCCOSUM; FUNGUS CULTURE; HEADACHE; HEMOLYTIC ANEMIA; HOST RESISTANCE; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LEUKOPENIA; LIBIDO DISORDER; LIVER TOXICITY; MALASSEZIA; MEMORY DISORDER; MICROSPORUM; NAUSEA; NEURITIS; NEUTROPENIA; ONYCHOMYCOSIS; PATHOGENESIS; PHOTOSENSITIVITY; PRURITUS; RASH; REVIEW; RHINITIS; SKIN LUPUS ERYTHEMATOSUS; TINEA BARBAE; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA FACIEI; TINEA MANUUM; TINEA PEDIS; TINEA VERSICOLOR; TRICHOPHYTON; URTICARIA; VISUAL DISORDER; VOMITING;

EID: 0037367097     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(02)00065-X     Document Type: Review

References (34)

1. Zuber T, Baddam K. Superficial fungal infection of the skin: where and how it appears help determine therapy. Postgrad Med 2001;109:117-32.
2. Hossain M, Ghannoum M. New developments in chemotherapy for non-invasive fungal infections. Expert Opin Investig Drugs 2001;10:1-11.
3. Ghannoum M, Hajjeh R, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43:641-8.
4. Goldstein A, Smith K, Ives T, et al. Mycotic infections: effective management of conditions involving the skin, hair, and nails. Geriatrics 2000;55:40-52.
5. Rippon J. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd edition. Philadelphia: WB Saunders; 1988.
6. Dermatophytosis. Mycology online. Available at: www.mycology.adelaide.edu.au. Accessed September 2001.
7. Bennett M, Fleischer A, Loveless J, et al. Oral griseofulvin remains the treatment of choice for tinea captitis in children. Pediatr Dermatol 2000;17:304-9.
8. Elewski B. Tinea capitis: a current perspective. J Am Acad Dermatol 2000;42(1 pt 1):1-20.
9. Charif M, Elewski B. A historical perspective on onychomycosis. Dermatol Ther 1997; 3:43-5.
10. Svejgaard E. Recalcitrant dermatophyte infection. Dermatol Ther 1997;3:75-8.
11. Gupta A, DeDoncker P, Degreef H. Tinea manus treated with 1-week itraconazole vs. terbinafine. Int J Dermatol 2000;39:521-38.
12. Amsden G, Elewski B, Ghannoum M, et al. Managing onychomycosis: issues in diagnosis, treatment, and economics. Available at: www.mesinc.com/education/monographs2/ cme023/index.html. 1999. Accessed September 2001.
13. Del Rosso J. Current management of onychomycosis and dermatomycoses. Curr Infect Dis Rep 2000;2:438-45.
14. McClellan K, Wiseman L, Markham A. Terbinafine: an update of its use in superficial mycoses. Drugs 1999;58:179-202.
15. Stary A, Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology 1998;196:237-41.
16. Elewski B. Treatment of tinea capitis: beyond griseofulvin. J Am Acad Dermatol 1999; 40(6 pt 2):S27-30.
17. Hamm H, Schwinn A, Brautigam M, et al. Short duration treatment with terbinafine for tinea captitis caused by Trichophyton or Microsporum species. Br J Dermatol 1999;140: 480-2.
18. Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25, 884 patients. Arch Dermatol 1997; 133:1213-9.
19. De Rosso J, Gupta A. Oral itraconazole therapy for superficial, subcutaneous, and systemic infections: a panoramic view. Postgrad Med 1999;46-52.
20. Elewski B. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1999; 133:1172-3.
21. Perea S, Ramos M, Garau M, et al. Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. J Clin Microbiol 2000;38:3226-30.
22. Albreski D, Gupta A, Gross E. Onychomycosis in diabetes; management considerations. Postgrad Med 1999;26-30.
23. Durden F, Elewski B. Fungal infections in HIV-infected patients. Semin Cutan Med Surg 1997;16:200-12.
24. Evans E. Resistance of Candida species to antifungal agents used in the treatment of onychomycosis: a review of current problems. Br J Dermatol 1999; 141(suppl 56):33-5.
25. Amadio P. Fungal infections of the hand. Hand Clin 1998; 14:605-12.
26. Evans E, Sigurgeirsson B. Double-blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ 1999; 318:1031-5.
27. Havu V, Brandt H, Heikkila H, et al. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. Br J Dermatol 1999;140:96-101.
28. Zaias N. Onychomycosis treated until the nail is replaced by normal growth or there is failure. Arch Dermatol 2000;136:940.
29. Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrheic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 2000;38:337-41.
30. Lesher J. Oral therapy of common superficial fungal infections of the skin. J Am Acad Dermatol 1999;40:S31-4.
31. Amichai B, Grunwald M. Adverse drug reactions of the new oral antifungal agentsterbinafine, fluconazole, and itraconazole. Int J Dermatol 1998;37:410-5.
32. Brodell R, Elewski B. Antifungal drug interactions: avoidance requires more than memorization. Postgrad Med 2000;107:41-3.
33. Katz H. Possible drug interactions in oral treatment of onychomycosis. J Am Podiatr Med Assoc 1997;87:571-4.
34. Moossavi M, Bagheri B, Scher R. Systemic antifungal therapy. Dermatol Clin 2001;19: 35-52.